SHL Telemedicine Ltd., a leading provider of advanced personal telemedicine solutions, is proud to announce that the full results of the Imperial College London TELE-ACS clinical trial have been chosen for presentation at the esteemed American College of Cardiology’s 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in Atlanta. The Company is thrilled to have the opportunity to share this groundbreaking research on a global platform.
The TELE-ACS clinical trial, conducted in collaboration with Imperial College London, focused on the use of telemedicine in the treatment of acute coronary syndrome (ACS) patients. The trial aimed to evaluate the effectiveness of SHL’s telemedicine solutions in improving patient outcomes and reducing healthcare costs for ACS patients. The results of the trial are highly anticipated within the medical community and are expected to provide valuable insights into the role of telemedicine in cardiac care.
The ACC 24 LBCT offers a prestigious platform for the presentation of cutting-edge clinical research in the field of cardiology. The selection of the TELE-ACS trial results for presentation at this event highlights the significance of the research and underlines the potential impact of SHL’s telemedicine solutions in the field of cardiovascular care. The Company is honored to have the opportunity to showcase its contributions to the advancement of telemedicine in cardiology on such an esteemed international stage.
The presentation of the TELE-ACS trial results at the ACC 24 LBCT represents a significant milestone for SHL Telemedicine Ltd. It demonstrates the Company’s commitment to driving innovation and advancing the field of telemedicine through rigorous clinical research and collaboration with leading academic institutions. The findings of the trial have the potential to transform the way ACS patients are managed and treated, and the Company is proud to be at the forefront of this important work.
SHL Telemedicine Ltd. is dedicated to providing cutting-edge telemedicine solutions that improve patient outcomes and enhance the delivery of healthcare services. The selection of the TELE-ACS trial results for presentation at the ACC 24 LBCT is a testament to the Company’s leadership in the field of telemedicine and its contribution to the advancement of cardiac care. The Company looks forward to sharing the results of the trial with the global cardiology community and is excited about the potential impact of this research on the future of telemedicine in cardiovascular care.
In conclusion, SHL Telemedicine Ltd. is honored to announce the selection of the full results of the TELE-ACS clinical trial for presentation at the ACC 24 LBCT. The Company is proud to be at the forefront of advancing telemedicine in the field of cardiology and is committed to driving innovation through rigorous clinical research and collaboration with leading academic institutions. The presentation of the TELE-ACS trial results at this prestigious event represents a significant milestone for SHL Telemedicine Ltd. and underlines the potential impact of its telemedicine solutions on the future of cardiovascular care.
Source link
